W hen BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some ...

Q1 2025 Management View CEO Matthew Gline described the quarter as "relatively quiet" ahead of an "exciting, busy fall," ...

Kennedy is vowing to "fix" the federal program for compensating Americans injured by vaccines, opening the door to sweeping changes for a system long targeted by anti-vaccine activists.

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

Patients in England with advanced head and neck cancer are being fast-tracked into a groundbreaking mRNA cancer vaccine trial, a ...

Adams warns cutting funding for mRNA vaccine research will cost lives, derail medical progress, and give China an advantage.

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Bildnachweis: Trophic Communications, VC Magazin, Pixabay. With over three decades in strategic communications and a track record with leaders like BioNTech and Tubulis, Gretchen Schweitzer brings ...

CureVac ( (CVAC)) has provided an announcement. On August 7, 2025, CureVac announced the resolution of U.S. patent litigation with Pfizer/BioNTech concerning mRNA-based COVID-19 vaccines. As part of ...

NHS England's collaboration with BioNTech is crucial in discovering individuals who may benefit from the trial.